73 results about "Immunohis tochemistry" patented technology

In alternative embodiments, provided are chimeric, synthetic or recombinant antibodies (Ab) against the human homologous box NKX-2. 1 (also known as NK2 homologous box 1, or thyroid transcription factor 1 (TTF-1)) protein, including articles of manufacture and kits comprising them, and methods of making and using them, including, for example, their use in the detection or diagnosis and treatment of cancer. In alternative embodiments, an anti-NKX-2. 1 (TTF-1) antibody provided herein is used with an agent for determining whether NKX-2. 1 (TTF-1) expression or activity is present, reduced or deleted; or the sensitivity of the specific binding of the Ab or the antigen (Ag) binding fragment or protein (ABP) or the monomer or dimer ABP provided by the invention with the squamous cell carcinoma cells is lower than the sensitivity of the specific binding with the adenocarcinoma cells (or binding with lower affinity), so that false positives of the squamous cell carcinoma are less, and the positive recognition of the lung adenocarcinoma is better.

This provides a system and method for analyzing and diagnosing conditions, such as cancer, based upon stained tissue sample slides prepared by users from patient tissue taken, for example, in a biopsy procedure. A convolutional neural network (CNN) is generated at training time. Slide images are acquired / scanned, and individual cell nuclei from the images are annotated, using IHC. H&E images are acquired / scanned prior to a washout intermediate step from the same slides / tissue samples. IHC is performed on the same tissue layer, which was scanned and used to retrospectively annotate the H&E WSI. IHC is used to annotate a ground truth mask for machine learning. The resultant process achieves a high degree of spatial resolution in detecting individual IHC positive nuclei, yielding process that is almost entirely automated, employing materials that are commonly available in clinical practice. In runtime, users access the CNN to perform analysis on patient slides.

The invention discloses an anti-soluble transferrin receptor monoclonal antibody as well as a preparation method and application thereof, and belongs to the technical field of antibody detection. According to the antibody, an L101-F760 amino acid sequence of human TfR protein is used as an immunogen, specific screening of B cells, reverse RNA (Ribonucleic Acid) into cDNA (Complementary Deoxyribose Nucleic Acid) through RT-PCR (Reverse Transcription-Polymerase Chain Reaction), then homologous recombination is performed to construct heavy and light chain vectors, and finally multiple rounds of screening are performed to obtain the purified sTfR monoclonal antibody, so that the sTfR protein can be specifically recognized, and the antibody has the advantages of high specificity and high sensitivity and can be widely applied to the field of immunotherapy. The natural sTfR protein in human serum can be recognized. The kit is applied to the detection and screening fields of immunohistochemistry, immunofluorescence chemistry, western blot, co-immunoprecipitation, indirect ELISA, flow cytometry and the like, especially has low background and no interference of non-specific binding impure protein during immunohistochemistry detection, can obtain more accurate detection and evaluation results, avoids interference of false positive and false negative, and has high detection accuracy. The method has great application value in the aspects of basic scientific research and clinical pathology detection.

The invention relates to the technical field of immune globulin, in particular to an anti-human BCOR protein monoclonal antibody and a hybridoma cell strain and application thereof. The invention provides an anti-human BCOR protein monoclonal antibody which is secreted by a hybridoma cell strain OTI3D11, the hybridoma cell strain OTI3D11 is preserved in the China General Microbiological Culture Collection Center (CGMCC) on November 28, 2024, and the preservation number of the hybridoma cell strain OTI3D11 is CGMCC No.46244. The anti-human BCOR protein monoclonal antibody can be used for preparing anti-human BCOR protein. The anti-human BCOR protein monoclonal antibody secreted by the hybridoma cell strain OTI3D11 disclosed by the invention has very high specificity and sensitivity. Therefore, the anti-BCOR monoclonal antibody secreted by the hybridoma cell strain OTI3D11 can be used for immunohistochemical detection so as to detect the expression condition of related tumor BCOR, and a basis is provided for diagnosis of patients by clinical doctors.

The invention discloses a fluorescence coding probe and a single cell immunoblotting method. The nucleic acid tag comprises oligonucleotide chains f1, f2... fn, n is greater than 2, each oligonucleotide chain contains a fluorophore and a quenching group, partial sequences of the next oligonucleotide chain and the previous oligonucleotide chain are complementarily paired, and the quenching group of the next oligonucleotide chain quenches the fluorophore of the previous oligonucleotide chain. Also disclosed is a quenching tag comprising a complementary strand capable of complementary pairing with an oligonucleotide strand in a nucleic acid tag. The invention discloses a fluorescent coding probe comprising a nucleic acid label, a preparation method of the fluorescent coding probe and application of the fluorescent coding probe in a multi-target single-cell immunoblotting technology, an immunofluorescence technology and an immunohistochemical staining technology. According to the fluorescence-coded multi-target single-cell immunoblotting method disclosed by the invention, multi-target protein detection can be carried out by utilizing limited fluorescence channels, the signal loss is small, and the expansibility is high.

The invention discloses an enzyme-labeled secondary antibody polymer for immunohistochemical staining. The enzyme-labeled secondary antibody polymer is formed by combining a secondary antibody and a polymer skeleton, the polymer is labeled by a labeling enzyme, the polymer skeleton is polymethylacrylic acid-2-hydroxyethyl ester, and the labeling enzyme is connected to the polymethylacrylic acid-2-hydroxyethyl ester through a coupling agent. According to the invention, polymethylacrylic acid-2-hydroxyethyl ester is used for modifying protein, so that the immunogenicity and antigenicity are reduced, the hydrolysis of protease can be weakened, and the solubility of protein molecules is improved. The enzyme-labeled secondary antibody polymer is applied to immunohistochemical staining and has high specificity and sensitivity.

The invention relates to the technical field of medical imaging, in particular to a breast cancer tissue HER2 automatic scoring method and device based on a characteristic curve, and the method comprises the steps: carrying out the reading operation of a full-slice image of immunohistochemical staining; extracting a target region of interest of the full slice image; slicing and screening the target region of interest to obtain a plurality of image slices; calculating a percentage-saturation characteristic curve of each image slice, and extracting characteristic information of the percentage-saturation characteristic curve; based on the feature information of the percentage-saturation feature curve, performing preliminary HER2 scoring on each image slice in combination with a rule base and a logistic regression classification algorithm; and integrating the scoring results of the image slices, and outputting a final HER2 score and a characteristic curve visualization graph. According to the method, the feature curve is combined with the rule base and the logistic regression classification algorithm, so that the objectivity of HER2 scoring is improved, and the problems of subjectivity and low efficiency of manual evaluation are reduced.

The invention discloses application of a reagent for detecting REEP protein in preparation of a product for diagnosing prostatic cancer, and relates to the technical field of biological medicine. Proteome analysis on urine proteins of a prostate cancer patient and a normal male and immunohistochemical analysis on archive wax blocks and surrounding normal prostate tissues of the prostate cancer patient find that REEP5 and REEP6 proteins are highly expressed in the prostate cancer tissues, and the content of REEP5 and REEP6 proteins in urine is higher than that of the normal group; the REEP5 protein and the REEP6 protein have a certain relationship with occurrence and development of the prostate cancer, are helpful for diagnosis of the prostate cancer and are also helpful for detection and diagnosis of noninvasive urine prostate cancer, and through research on the relationship between the REEP5 protein and the REEP6 protein and the prostate cancer, the diagnosis rate of a patient is increased, early discovery and early treatment are realized, postoperative noninvasive review, medication guidance and self-test are also facilitated, and the prostate cancer diagnosis method is suitable for clinical application. The survival rate and the cure rate are improved.

The present disclosure provides antibodies, including but not limited to monoclonal antibodies, capable of specifically binding the human PAX8 protein. Also provided are nucleic acids encoding the anti-PAX8 antibodies described herein, as well as expression vectors comprising these nucleic acids, host cells transformed with the expression vectors comprising the nucleic acids encoding the anti-PAX8 antibodies, and methods of making the antibodies. The anti-PAX8 antibodies described herein are useful for immunohistochemical detection of human PAX8 protein in tissue samples.

The invention discloses application of HBG protein in preparation of a product for auxiliary diagnosis of prostate cancer, and relates to the technical field of biological medicine. The application way is as follows: the reagent for specifically detecting HBG protein expression in a biological sample is used for preparing a product for auxiliary diagnosis of prostate cancer. Proteome analysis on urine proteins of a prostate cancer patient and a normal male shows that the concentration of the HBG1 protein in the urine of the prostate cancer patient is obviously higher than that of the normal male group, and immunohistochemical analysis on archive wax blocks and paracancerous normal prostate tissues of the prostate cancer patient shows that the HBG1 protein can be applied to the prostate cancer patient. The HBG1 and HBG2 proteins are strongly positive in prostate cancer tissues and are low-expressed or non-expressed in normal prostate tissues, which indicates that the HBG1 and HBG2 proteins have a certain relationship with the occurrence and development of the prostate cancer, can be used for assisting the diagnosis of the prostate cancer and the diagnosis of difficult cases, and can also be used for the review after the treatment of the prostate cancer, so as to improve the diagnosis rate and the survival rate of patients.

Here provided an antibody YWHG-1 against HLA-G molecule and use thereof. The antibody is produced by the hybridoma deposited under CCTCC NO: 202120, and is prepared by an immunogen with amino acids which are common to seven known HLA-G isoforms (HLA-G1, HLA-G2, HLA-G3, HLA-G4, HLA-G5, HLA-G6 and HLA-G7) which is located at positions 72-91 (QTDRMNLQTLRGYYNQSEAS) in the heavy chain α1 domain of the HLA-G molecule. The present invention provides nucleotides encoding the antibody YWHG-1 and encoded amino acid sequences thereof. The antibody YWHG-1 can be used for immunohistochemistry, immunoblotting, flow cytometry and other assays for HLA-G isoforms.

The application discloses application of a reagent for detecting AHSP protein in preparation of a product for diagnosing prostate cancer, and relates to the technical field of biological medicine; through proteomic analysis, ELISA test on urine protein of prostate cancer patients, clear cell renal cell carcinoma patients and normal healthy men, and immunohistochemical analysis on file wax blocks of the prostate cancer patients, normal prostate tissues around the cancer, prostate tissues of prostatic hyperplasia and clear cell renal cell carcinoma tissues, it is found that the AHSP protein has a certain relationship with the occurrence and development of prostate cancer, and can be used for assisting diagnosis of the prostate cancer; and in urine detection, AHSP has higher sensitivity than PSA, and when PSA is negative or serum PSA is low, AHSP can form complementation with ASHP, thereby helping to improve the diagnosis rate and non-invasive screening ability; through research on the relationship between the AHSP protein and the prostate cancer, the diagnosis rate of patients can be improved, non-invasive reexamination after treatment is facilitated, drug use is guided, and the survival rate is improved.

The present invention provides an anti-VEGFR2 nanobody and its application. The amino acid sequence and nucleotide sequence of the anti-VEGFR2 nanobody of the present invention are shown in SEQ ID No.1 and SEQ ID No.2 respectively. The anti-VEGFR2 nanobody provided by the present invention can specifically bind to the VEGFR2 protein, and the sensitivity to the VEGFR2 protein is 0.625 μg / mL. The application of the anti-VEGFR2 nanobody can be used for immunohistochemistry and Western Blotting to detect the expression of VEGFR2 in tissues or cells, providing a method for the study of the function of the VEGFR2 gene.

The invention belongs to the technical field of immunoassay, and particularly relates to an immunohistochemical multicolor display method under a bright field microscope. The method comprises the following steps: developing a to-be-detected tissue sample by adopting a color combination of yellow, red, green or yellow, purple and cyan blue in sequence; the to-be-detected tissue sample comprises a tumor lymph tertiary structure, infiltrating lymphocytes, urothelium cancer cells, non-small cell lung cancer and prostatic cancer. According to the color developing method of the color combination mode, qualitative and quantitative detection of the to-be-detected tissue can be achieved. According to the staining and developing method provided by the invention, the diagnosis time is saved, the diagnosis efficiency is improved, and signals which are originally required to be displayed on three pathological sections can be concentrated on one section to be displayed at the same time.

This invention discloses the application of SNCG protein in the auxiliary diagnosis of prostate cancer, belonging to the field of biomedical technology. The application involves using reagents specifically designed to detect SNCG protein expression in biological samples to prepare products for the auxiliary diagnosis of prostate cancer. Through proteomic analysis of urinary proteins from prostate cancer patients and normal men, this invention revealed that the concentration of SNCG protein in the urine of prostate cancer patients was significantly higher than that in the normal male group. Immunohistochemical analysis of paraffin-embedded tissue samples from prostate cancer patients and surrounding normal prostate tissue showed that SNCG protein has a certain expression rate in prostate cancer, and that SNCG protein is also expressed in the basal cells of normal prostate glands, indicating a certain relationship between SNCG protein and the occurrence and development of prostate cancer. This invention can be used to assist in the diagnosis of prostate cancer and difficult cases, thereby improving the diagnosis rate and survival rate of patients.

The application discloses application of YW2301 in preparation of a medicine for resisting Burkitt lymphoma, utilizes CCK8 cell activity experiment to detect the inhibition ability of YW2301 on Raji and CA46 cell proliferation, constructs a NON / SCID subcutaneous transplantation tumor model by using a Raji cell line, evaluates the therapeutic significance of YW2301 on Burkitt lymphoma, YW2301 can effectively inhibit the tumorigenicity of Burkitt lymphoma cells and the growth speed of the transplantation tumor, and adopts immunohistochemical staining to detect the ALDH18A1 and c-Myc protein expression in a Burkitt lymphoma transplantation tumor tissue section, YW2301 can effectively down-regulate the ALDH18A1 and c-Myc protein expression in a Burkitt lymphoma tissue, and further proves that YW2301 can be used as a candidate small molecule for targeted treatment of Burkitt lymphoma.

This provides a system and method for analyzing and diagnosing conditions, such as cancer, based upon stained tissue sample slides prepared by users from patient tissue taken, for example, in a biopsy procedure. A convolutional neural network (CNN) is generated at training time. Slide images are acquired / scanned, and individual cell nuclei from the images are annotated, using IHC. H&E images are acquired / scanned prior to a washout intermediate step from the same slides / tissue samples. IHC is performed on the same tissue layer, which was scanned and used to retrospectively annotate the H&E WSI. IHC is used to annotate a ground truth mask for machine learning. The resultant process achieves a high degree of spatial resolution in detecting individual IHC positive nuclei, yielding process that is almost entirely automated, employing materials that are commonly available in clinical practice. In runtime, users access the CNN to perform analysis on patient slides.

The invention discloses a NaPi2b extracellular domain antigen protein fragment as well as a preparation method and application thereof, according to a pre-designed amino acid sequence shown as SEQ ID NO: 1, escherichia coli codon optimization is performed, then a target gene is synthesized, and the gene sequence is shown as SEQ ID NO: 2; the gene segment is inserted into an expression plasmid between the NdeI and the HindIII; and carrying out plasmid transformation and screening, protein induced expression and protein purification to prepare the antigen protein fragment. The antigen fragment can be used for generating a corresponding NaPi2b antibody through animal immune response, and the antibody can be used for detecting the expression condition of NaPi2b protein in a human tissue sample by an immunohistochemical method, and is also used for an accompanying diagnostic kit of a humanized NaPi2b antibody coupling medicine, so that the aim of assisting in precise medication is fulfilled.

A method for pre-treatment identification of cancer patients that respond to anti-CLEVER-1 therapy comprising an administration of an agent capable of binding to CLEVER-1 in a patient. In the method, the presence of CLEVER-1 expressing cells is detected in a tumor sample obtained from a cancer patient, by immunohistochemistry staining by a mouse monoclonal IgG2a kappa STAB-1 antibody (clone 4G9), and a percentage of intra-tumoral CLEVER-1 expressing cells from the total amount of viable intra-tumoral cells present in the stained sample is calculated. A tumor sample which shows substantial percentage of CLEVER-1 expressing intra-tumoral cells is an indication that the cancer patient is responsive to the anti-CLEVER-1 therapy.

The present application relates to the technical field of biology, and particularly discloses a kind of tyrosine iodination modified PP2A protein monoclonal antibody, preparation method and application.The present application is prepared by tyrosine iodination modified PP2A protein antigen peptide, rabbit is immunized to prepare monoclonal antibody, and is selected by phage display technology, expression vector amplification and ELISA screening, finally obtains a strain of monoclonal antibody R004 that can effectively recognize target.The antibody shows good sensitivity and specificity in immunohistochemistry, cell immunofluorescence and protein immunoblotting.The monoclonal antibody screened in the present application can be used in the detection of tyrosine iodination modification of PP2A protein catalytic subunit 307, and provides support for tumor diagnosis, anti-tumor and neurological disease drug research and development.

A laboratory immunohistochemical staining slide fixing and auxiliary operation apparatus, comprising an immunohistochemical staining slide fixing apparatus (1), a storage box (5), and a dedicated filter box for coverslipping (6). The immunohistochemical staining slide fixing apparatus (1) comprises a slide grasping spring (11), a first handle (12) and a second handle (13), one end of the first and second handles (12, 13) being fixed to two sides of the slide grasping spring (11), respectively, and the other ends each being bent inward to form first and second gripping parts (14, 15). By means of squeezing the handles (12, 13) to drive the top of the slide grasping spring (11) to arch open, multiple staining slides (2) can be inserted and positioned on the slide grasping spring (11); releasing the spring (11) can clamp and fix the slides (2) for subsequent batch immunohistochemical staining operations, such as staining and washing, significantly improving experiment efficiency. The storage box (5) enables centralized storage of multiple slide fixing apparatuses (1), preventing small fixing apparatuses (1) from being lost due to random placement, and reducing laboratory losses. The dedicated filter box for coverslipping (6) is used to place a slide (2) to be coverslipped on a filter mesh thereof for coverslipping processing, allowing residual xylene on the slide (2) to be centrally recovered, and thereby improving laboratory environmental safety and the personal safety of operators.

w The invention discloses a detection method for predicting efficacy and prognosis of immunotherapy for small cell lung cancer based on ATAD2 expression, and relates to the technical fields of molecular biology and cancer treatment. The method comprises the following steps: extracting a tumor tissue sample of a small cell lung cancer patient through surgical resection; Detecting the tumor tissue sample to obtain ATAD2 expression level, wherein the detection adopts an immunohistochemical staining method. According to the invention, the expression level of ATAD2 in tumor tissues of small cell lung cancer is quantitatively evaluated by immunohistochemical detection technology, and the molecular marker information is systematically correlated with the clinical and pathological characteristics of patients by combining Cox regression analysis and Logistic regression analysis, so that the comprehensive prediction of immunotherapy efficacy and patient survival time is realized.

The invention discloses application of SNCG protein in auxiliary diagnosis of prostate cancer, and relates to the technical field of biological medicine. The application way is as follows: the reagent for specifically detecting the expression of the SNCG protein in a biological sample is used for preparing a product for auxiliary diagnosis of the prostate cancer. Proteome analysis on urine proteins of a prostate cancer patient and a normal male shows that the concentration of the SNCG protein in the urine of the prostate cancer patient is obviously higher than that of the normal male group, and immunohistochemical analysis on archive wax blocks and surrounding normal prostate tissues of the prostate cancer patient shows that the SNCG protein can be applied to the prostate cancer patient. The SNCG protein has a certain expression rate in the prostate cancer, which indicates that the SNCG protein has a certain relationship with the occurrence and development of the prostate cancer, and can be used for assisting the diagnosis of the prostate cancer and the diagnosis of difficult cases so as to improve the diagnosis rate and the survival rate of patients.

Inventors analyzed the prognostic value of tumor and stromal-derived SPARC in a large series that included 148 non-metastatic TNBC patients with a long follow-up by immunohistochemistry. They show that SPARC expression was detected in cancer cells (42.4%), cancer-associated fibroblasts (CATs) (88.1%). TAMs (77.1%), endothelial cells (75.2%) and TILs (9.8%). Recurrence-free survival (RFS) was significantly lower for patients with a positive expression of SPARC in CATs (SPARC+CATs) with a median follow-up of 5.4 years. SPARC expression in CATs was found to be an independent prognostic factor in multivariate analysis. Accordingly, the present invention relates to a method for predicting the survival time of a subject suffering from triple-negative breast cancer (TNBC) comprising determining the expression level of Secreted Protein Acidic and Rich in Cysteine (SPARC) in cancer-associated fibroblasts (CATs) in a biological sample obtained from the subject wherein said positive expression of SPARC in CATs (SPARC+CAFs) correlates with a short survival time of the subject.

A system and method are provided that uses a control tissue to perform color calibration and automate detection. The system can receive calibration images from the scanner. Each calibration image can depict a portion of a stained tissue sample having a known score value. The system can determine a correction function for the scanner based on the plurality of calibration images. The system can receive unscored slide images depicting the portions of the stained tissue. The unscored slide images can be captured by the scanner. The system can display scores for the unscored slide images generated using the correction function for the scanner in a graphical user interface of an application executed by the system.

The invention discloses a mitochondrial transcriptional regulatory factor Mt-CREB and application thereof in screening and preparing a drug for resisting brain aging. According to the present invention, based on the characteristic that the mitochondrial circular DNA has the conservative cAMP reaction element sequence CRE, the CREBWT capable of selectively identifying and combining the CRE or the amino acid RRPSYR mutant CREBDIEDML of the CREBWT at the 130-135th site is adopted as the key element of the gene enhancement regulation, and the CREBWT or the CREBDIEDML is selectively positioned to the mitochondria by using the mitochondrial targeting sequence so as to achieve the detection and the regulation of the mitochondrial gene expression enhancement; on one hand, the invention discloses an amino acid sequence of the Mt-CREBDIEDML, a nucleotide sequence for coding the Mt-CREBDIEDML, an expression vector containing the nucleotide sequence, and an application of the Mt-CREBDIEDML in preparation of a drug for resisting brain aging; on the other hand, the invention discloses a fluorescence and / or chemiluminiscence detection method for screening the anti-brain aging drugs by using the Mt-CREBWT. Through research on biochemical indexes, immunohistochemistry, gene expression level and the like, a new way is provided for preparing and screening anti-brain aging drugs and treating memory decline caused by aging.

This invention discloses an anti-ERBB2 monoclonal antibody, its preparation method, and its applications, belonging to the field of biomedical technology. This anti-ERBB2 monoclonal antibody uses the intracellular domain of the human ERBB2 protein as an immunogen and is obtained through animal immunization, B cell screening, gene cloning, and recombinant expression techniques. It can specifically recognize the human ERBB2 protein, exhibiting high affinity and high specificity, and can recognize both native and denatured ERBB2 proteins. This monoclonal antibody can be applied in immunohistochemistry, immunofluorescence, Western blotting (WB), flow cytometry, ELISA detection, and tumor targeted therapy. Experimental results show that this antibody has low background and no non-specific binding, accurately detecting ERBB2-overexpressing tumor cells and tissues, and has significant application value in the diagnosis, prognostic assessment, and targeted therapy of ERBB2-related diseases such as breast cancer.

The application relates to the field of health assessment, and particularly discloses a ZNF281-based gastric cancer prognosis value evaluation system, which comprises a ZNF281 expression quantification module, which is used for detecting the protein / RNA expression level of ZNF281 in tumor tissue through immunohistochemistry, real-time fluorescent quantitative PCR or Western blot technology; a stemness feature and signal path analysis module, which is used for acquiring the protein expression or cell positive rate of stemness genes CD44 and SOX9; then evaluating the activation state of an IL6 / JAK / STAT3 path, including Western blot detection of a p-STAT3 / STAT3 ratio, ELISA determination of IL6 and CXCL5 cytokine levels; then analyzing the cancer-associated fibroblast infiltration in a tumor microenvironment, quantifying the CAF density through alpha-SMA immunofluorescence staining, and combining single-cell sequencing analysis of the interaction strength of a CXCL5 / CXCR2 signal shaft. The technical scheme of the application can integrate the expression amount of ZNF281, signal path activity and clinical pathological data, and precisely stratify the chemotherapy sensitivity and prognosis of gastric cancer patients.

The invention discloses application of an RBSN detection reagent in preparation of a colorectal cancer detection / prognosis prediction product, and belongs to the technical field of colorectal cancer diagnosis markers. It is found through information generation analysis that compared with normal tissue, the expression level of RBSN in colorectal cancer tumor tissue is lower, and patients with high expression of RBSN have longer lifetime than patients with low expression of RBSN. RBSN expression differential genes are obviously enriched on related paths such as digestion and absorption of protein, ECM receptor interaction, proteoglycan in diabetic cardiomyopathy, oxidative phosphorylation, adherence, cancer, thermogenesis, chemical carcinogenesis of active oxygen and the like, and are positively correlated with immune infiltration. Immunohistochemical experiments prove that the coding protein Rabinosyn-5 of the RBSN is expressed in tumor tissues and para-carcinoma normal tissues of the colorectal cancer and is mainly expressed in cytoplasm, the expression of the RBSN is obviously related to the prognosis of the colorectal cancer patient, and the prognosis lifetime of the colorectal cancer patient with high expression of the RBSN is longer.

The invention discloses an environment-friendly biological tissue sample preparation sleeve solution and application thereof, and belongs to the technical field of application of pathological reagents in the pathology department. In order to solve the technical problems that in the prior art, in the tissue fixing and tissue wax block preparation process, the fixing effect is not ideal, fixing liquid and transparent liquid pollute the environment and harm human health, dehydration liquid is not thorough in dehydration, subsequent wax dipping liquid permeation is affected, wax blocks cannot be sliced, and the environment is polluted. The invention provides an environment-friendly biological tissue sample preparation set solution and application thereof, the preparation set solution is composed of a stationary solution, a dehydration solution and a transparent solution, and the stationary solution is composed of 40-70 parts of a protein fixing agent, 1-10 parts of a preservative, 1-5 parts of an osmotic pressure regulator, 2-5 parts of a wetting agent, 0.1-0.5 part of an antioxidant and 15-45 parts of purified water. The prepared sleeve solution can be applied to pathological histology and animal and plant specimen preparation, including conventional pathological diagnosis, immunohistochemical diagnosis technology, molecular biological diagnosis technology and the like.